Forte Biosciences stock (US34960P1012): Q1 2026 earnings report upcoming

Forte Biosciences (FBRX) will release Q1 2026 earnings on May 21, with shares closing at $24.66 on May 13 amid biotech sector volatility.

Forte Biosciences, a clinical-stage biotech firm, has its Q1 2026 earnings report scheduled for May 21, 2026, according to MarketBeat as of 05/13/2026. The NASDAQ-listed company focuses on treatments for autoimmune skin diseases like vitiligo and alopecia areata via its FB-102 program. Shares closed at $24.66 on May 13, 2026, up 1.52% that day, with extended trading at $24.62, per the same source.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Forte Biosciences, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: Dallas, Texas, United States
• Core markets: United States
• Key revenue drivers: Clinical-stage autoimmune treatments
• Home exchange/listing venue: Nasdaq (FBRX)
• Trading currency: USD

Forte Biosciences: core business model

Forte Biosciences operates as a clinical-stage biopharmaceutical company developing therapies to restore skin health by targeting immune responses in autoimmune diseases. Its lead candidate, FB-102, addresses conditions such as graft-versus-host disease, vitiligo, and alopecia areata, according to company information from fortebiorx.com as of 05/14/2026. Headquartered in Dallas, Texas, the firm advances its pipeline through clinical trials primarily in the US market.

The business model centers on immunology-focused innovation, with no commercial products yet generating revenue. Forte Biosciences relies on funding from equity offerings and partnerships to support R&D, positioning it as a high-risk, high-reward play typical in biotech for US investors tracking Nasdaq-listed clinical developers.

Main revenue and product drivers for Forte Biosciences

Currently pre-revenue, Forte Biosciences drives value through pipeline milestones, particularly FB-102 progress in Phase 2 trials for vitiligo and alopecia areata. Future revenue potential hinges on regulatory approvals and commercialization partnerships, as noted in investor materials. Analysts project EPS improvement from ($4.63) to ($4.35) over the next year, per MarketBeat as of 05/14/2026.

Key drivers include clinical data readouts and potential label expansions. The company's focus on dermatological autoimmunity taps into a growing US market, where treatments for conditions like alopecia areata exceed multi-billion-dollar opportunities, supporting long-term growth prospects amid upcoming Q1 earnings.

Industry trends and competitive position

The biotech sector, especially immunology and dermatology, sees robust US demand driven by advances in biologics and precision medicine. Forte Biosciences competes with players like NRx Pharmaceuticals in drug development, though it lags in some metrics per comparative data from MarketBeat as of 05/14/2026. Monthly performance showed a -12.52% decline in May 2026, reflecting sector volatility, via StockTitan as of 05/14/2026.

Why Forte Biosciences matters for US investors

Listed on Nasdaq, Forte Biosciences offers US investors exposure to innovative dermatology therapies amid rising autoimmune disease prevalence. Its Texas base and US-centric trials align with domestic healthcare spending trends, making it relevant for portfolios focused on clinical-stage biotechs with potential breakthrough designations.

Conclusion

Forte Biosciences approaches its Q1 2026 earnings on May 21 with a stable share price around $24.66 as of May 13 and ongoing FB-102 development. While pre-revenue status introduces risks, pipeline progress in autoimmune dermatology offers milestones for observation. US investors may track Nasdaq volatility and trial updates for context on this clinical-stage biotech.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.